Coca Cola 2010 Annual Report Download - page 161

• Charge of $16 million for Bottling Investments, primarily attributable to the Company’s proportionate share of
unusual tax charges and transaction costs recorded by equity method investees. Refer to Note 17.
• A net tax charge of $16 million related to amounts required to be recorded for changes to our uncertain tax
positions, including interest and penalties. Refer to Note 14.
In the third quarter of 2010, the Company recorded the following transactions which impacted results:
• Charges of $1 million for Eurasia and Africa, $13 million for Europe, $8 million for Pacific, $12 million for
Bottling Investments and $68 million for Corporate, primarily due to the Company’s ongoing productivity,
integration and restructuring initiatives and transaction costs incurred in connection with our acquisition of
CCE’s North American business and the sale of our Norwegian and Swedish bottling operations to New CCE.
These charges were partially offset by a $2 million benefit for North America due to the refinement of previously
established restructuring accruals. Refer to Note 17 and Note 18.
• Charge of $10 million for Bottling Investments. This net charge was primarily attributable to the Company’s
proportionate share of transaction costs recorded by CCE, which was partially offset by our proportionate share
of a foreign currency remeasurement gain recorded by an equity method investee. The components of the net
charge were individually insignificant. Refer to Note 17.
• Gain of $23 million for Corporate due to the sale of 50 percent of our investment in Le˜ ao Junior. Refer to
Note 2 and Note 17.
• A net tax charge of $13 million related to amounts required to be recorded for changes to our uncertain tax
positions, including interest and penalties. Refer to Note 14.
The Company’s fourth quarter of 2010 results were impacted by one additional shipping day as compared to the fourth
quarter of 2009. Additionally, the Company recorded the following transactions which impacted results:
• Charges of $3 million for Eurasia and Africa, $7 million for Europe, $125 million for North America, $9 million
for Pacific, $66 million for Bottling Investments and $335 million for Corporate, primarily due to the Company’s
productivity, integration and restructuring initiatives, charitable donations, transaction costs incurred in
connection with our acquisition of CCE’s North American business and the sale of our Norwegian and Swedish
bottling operations to New CCE and other charges related to bottling activities in Eurasia. Refer to Note 17 and
Note 18.
• Charge of $74 million for North America due to the acceleration of expense associated with certain share-based
replacement awards issued in connection with our acquisition of CCE’s North American business. Refer to
Note 17.
• Charge of $20 million for North America due to the amortization of favorable supply contracts acquired in
connection with our acquisition of CCE’s North American business. Refer to Note 17.
• Charge of $11 million for Bottling Investments, primarily attributable to the Company’s proportionate share of
restructuring charges recorded by equity method investees. Refer to Note 17.
• Benefit of $4,978 million for Corporate due to the remeasurement of our equity investment in CCE to fair value
upon the close of the transaction. Refer to Note 2 and Note 17.
• Charge of $265 million for Corporate due to expenses related to preexisting relationships with CCE. These
expenses primarily related to the write-off of our investment in infrastructure programs with CCE. Refer to
Note 2 and Note 17.
• Gain of $597 million for Corporate due to the sale of our Norwegian and Swedish bottling operations to New
CCE. Refer to Note 2 and Note 17.
• Charge of $342 million for Corporate related to the premiums paid to repurchase the long-term debt and the
costs associated with the settlement of treasury rate locks issued in connection with the debt tender offer. Refer
to Note 10.
• Charge of $22 million for Corporate due to an other-than-temporary impairment of an equity method investment
and a donation of preferred shares in one of our equity method investees. Refer to Note 16 and Note 17.
159